There has been much talk recently about the possible benefits of medicines derived from cannabis plants. With public pressure on governments to relax legislation, and increasing enthusiasm for investors, how positive is the prospect for these products?

In a series of two articles, Medilink EM Patron Mills and Reeve consider some of the recent changes to policy and approach, and obstacles that stand in the way for developers.

To read more, click here

Latest Opportunities

Exporting Starts Here programme for West Midlands companies

West Midlands Combined Authority (WMCA), funded by the UK Shared Prosperity Fund (UKSPF), has commissioned…

NIHR i4i Connect funding call

The NIHR Invention for Innovation (i4i) programme is accepting outline applications to their latest researcher-led Connect funding…

Study brief: The effects of a recovery gel on endurance cycling performance in the heat

The popularity of endurance sports like cycling and running has grown significantly over the past…

Latest News

Blog: Why cleanrooms are essential for medical-grade cannabis companies

By Medilink Midlands Member Airology Systems The demand for medical-grade cannabis has surged in recent…

Australia’s Cannim partners with PHTA to advance medicinal cannabis research

Leading medicinal cannabis company Cannim has announced its UK operations will be based at Birmingham’s…

New sleep trial shows dramatic benefits for participants

Cambridge Sleep Sciences (CSS), a leading UK innovator in sleep technology, has announced groundbreaking results…